Literature DB >> 26404131

Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.

K D M Nakamura1, T M Tilli2, J L Wanderley3, A Palumbo1, R M Mattos1, A C Ferreira4, C E Klumb4, L E Nasciutti1, E R Gimba5,6.   

Abstract

Osteopontin (OPN) is a phosphoprotein that activates several aspects of tumor progression. Alternative splicing of the OPN primary transcript generates three splicing isoforms, OPNa, OPNb and OPNc. In this report, we investigated some cellular mechanisms by which OPN splice variants could mediate PC3 prostate cancer (PCa) cell survival and growth in response to docetaxel (DXT)-induced cell death. Cell survival before and after DXT treatment was analyzed by phase-contrast microscopy and crystal-violet staining assays. Quantitative real-time PCR and immunocytochemical staining assays were used to evaluate the putative involvement of epithelial-mesenchymal transition (EMT) and OPN isoforms on mediating PC3 cell survival. Upon DXT treatment, PC3 cells overexpressing OPNb or OPNc isoforms showed higher cell densities, compared to cells overexpressing OPNa and controls. Notably, cells overexpressing OPNb or OPNc isoforms showed a downregulated pattern of EMT epithelial cell markers, while mesenchymal markers were mostly upregulated in these experimental conditions. We concluded that OPNc or OPNb overexpression in PC3 cells can mediate resistance and cell survival features in response to DXT-induced cell death. Our data also provide evidence the EMT program could be one of the molecular mechanisms mediating survival in OPNb- or OPNc-overexpressing cells in response to DXT treatment. These data could further contribute to a better understanding of the mechanisms by which PCa cells acquire resistance to DXT treatment.

Entities:  

Keywords:  Cell survival; Docetaxel; Osteopontin; Prostate cancer; Splicing isoforms

Mesh:

Substances:

Year:  2015        PMID: 26404131     DOI: 10.1007/s13277-015-4095-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  41 in total

Review 1.  The changing landscape in metastatic castration-resistant prostate cancer.

Authors:  Raya Leibowitz-Amit; Anthony M Joshua
Journal:  Curr Opin Support Palliat Care       Date:  2013-09       Impact factor: 2.302

2.  Upregulation of drug transporter expression by osteopontin in prostate cancer cells.

Authors:  I-Shan Hsieh; Wei-Hsun Huang; Houng-Chi Liou; Woei-Jer Chuang; Rong-Sen Yang; Wen-Mei Fu
Journal:  Mol Pharmacol       Date:  2013-02-22       Impact factor: 4.436

Review 3.  Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy.

Authors:  Subbareddy Maddika; Sudharsana Rao Ande; Soumya Panigrahi; Ted Paranjothy; Kazimierz Weglarczyk; Anne Zuse; Mehdi Eshraghi; Kamala D Manda; Emilia Wiechec; Marek Los
Journal:  Drug Resist Updat       Date:  2007-02-14       Impact factor: 18.500

Review 4.  Osteopontin: role in cell signaling and cancer progression.

Authors:  Hema Rangaswami; Anuradha Bulbule; Gopal C Kundu
Journal:  Trends Cell Biol       Date:  2006-01-10       Impact factor: 20.808

5.  Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.

Authors:  S G Patterson; S Wei; X Chen; D A Sallman; D L Gilvary; B Zhong; J Pow-Sang; T Yeatman; J Y Djeu
Journal:  Oncogene       Date:  2006-05-01       Impact factor: 9.867

Review 6.  Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.

Authors:  Michel D Wissing; Paul J van Diest; Elsken van der Wall; Hans Gelderblom
Journal:  Expert Opin Investig Drugs       Date:  2013-05       Impact factor: 6.206

7.  Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy.

Authors:  Romain Boidot; Frédérique Vegran; Sarab Lizard-Nacol
Journal:  Int J Mol Med       Date:  2009-02       Impact factor: 4.101

8.  Tumorigenic properties of alternative osteopontin isoforms in mesothelioma.

Authors:  Sergey V Ivanov; Alla V Ivanova; Chandra M V Goparaju; Yuanbin Chen; Amanda Beck; Harvey I Pass
Journal:  Biochem Biophys Res Commun       Date:  2009-03-13       Impact factor: 3.575

Review 9.  Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Authors:  Jiyong Liang; Joyce M Slingerland
Journal:  Cell Cycle       Date:  2003 Jul-Aug       Impact factor: 4.534

Review 10.  Osteopontin as a target for cancer therapy.

Authors:  Nicholas I F Johnston; Vignesh Kumar Gunasekharan; Amod Ravindranath; Ciara O'Connell; Patrick G Johnston; Mohamed K El-Tanani
Journal:  Front Biosci       Date:  2008-05-01
View more
  10 in total

1.  Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior.

Authors:  Luciana Bueno Ferreira; Catarina Tavares; Ana Pestana; Catarina Leite Pereira; Catarina Eloy; Marta Teixeira Pinto; Patricia Castro; Rui Batista; Elisabete Rios; Manuel Sobrinho-Simões; Etel Rodrigues Pereira Gimba; Paula Soares
Journal:  Oncotarget       Date:  2016-08-09

2.  Predictive value of stathmin-1 and osteopontin expression for taxan resistance in metastatic castrate-resistant prostate cancer.

Authors:  Asude Aksoy; Gokhan Artas; Omur Gokmen Sevindik
Journal:  Pak J Med Sci       Date:  2017 May-Jun       Impact factor: 1.088

3.  SIRT1 overexpression protects non-small cell lung cancer cells against osteopontin-induced epithelial-mesenchymal transition by suppressing NF-κB signaling.

Authors:  Xuejiao Li; Zhongxiu Jiang; Xiangmin Li; Xiaoye Zhang
Journal:  Onco Targets Ther       Date:  2018-03-02       Impact factor: 4.147

Review 4.  Human osteopontin: Potential clinical applications in cancer (Review).

Authors:  Chengcheng Hao; Yuxin Cui; Sionen Owen; Wenbin Li; Shan Cheng; Wen G Jiang
Journal:  Int J Mol Med       Date:  2017-04-21       Impact factor: 4.101

5.  Differential Effects of Autophagy-Related 10 Protein on HCV Replication and Autophagy Flux Are Mediated by Its Cysteine44 and Cysteine135.

Authors:  Miao-Qing Zhang; Jian-Rui Li; Zong-Gen Peng; Jing-Pu Zhang
Journal:  Front Immunol       Date:  2018-09-24       Impact factor: 7.561

6.  Osteopontin isoforms differentially promote arteriogenesis in response to ischemia via macrophage accumulation and survival.

Authors:  Grace Sanghee Lee; Hector F Salazar; Giji Joseph; Zoe Shin Yee Lok; Courtney M Caroti; Daiana Weiss; W Robert Taylor; Alicia N Lyle
Journal:  Lab Invest       Date:  2018-06-29       Impact factor: 5.662

Review 7.  Thromboinflammatory Processes at the Nexus of Metabolic Dysfunction and Prostate Cancer: The Emerging Role of Periprostatic Adipose Tissue.

Authors:  Ibrahim AlZaim; Aya Al-Saidi; Safaa H Hammoud; Nadine Darwiche; Yusra Al-Dhaheri; Ali H Eid; Ahmed F El-Yazbi
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

8.  Cinobufagin Suppresses The Characteristics Of Osteosarcoma Cancer Cells By Inhibiting The IL-6-OPN-STAT3 Pathway.

Authors:  Chuan Zhang; Kun Ma; Wu-Yin Li
Journal:  Drug Des Devel Ther       Date:  2019-12-04       Impact factor: 4.162

9.  Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer.

Authors:  Hongye Zhang; Ruiyu Wang; Mingxia Wang; Judong Luo; Changmin Liu
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

10.  Inducible T-Cell Costimulator Ligand Plays a Dual Role in Melanoma Metastasis upon Binding to Osteopontin or Inducible T-Cell Costimulator.

Authors:  Davide Raineri; Giuseppe Cappellano; Beatrice Vilardo; Federica Maione; Nausicaa Clemente; Elena Canciani; Elena Boggio; Casimiro Luca Gigliotti; Chiara Monge; Chiara Dianzani; Renzo Boldorini; Umberto Dianzani; Annalisa Chiocchetti
Journal:  Biomedicines       Date:  2021-12-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.